AU2009292908B2 - Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine - Google Patents

Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine Download PDF

Info

Publication number
AU2009292908B2
AU2009292908B2 AU2009292908A AU2009292908A AU2009292908B2 AU 2009292908 B2 AU2009292908 B2 AU 2009292908B2 AU 2009292908 A AU2009292908 A AU 2009292908A AU 2009292908 A AU2009292908 A AU 2009292908A AU 2009292908 B2 AU2009292908 B2 AU 2009292908B2
Authority
AU
Australia
Prior art keywords
fixed dose
dose combination
pharmaceutical oral
oral fixed
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009292908A
Other languages
English (en)
Other versions
AU2009292908A1 (en
Inventor
Stephen Valazza
Sudha Vippagunta
Robert Frank Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42040192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009292908(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009292908A1 publication Critical patent/AU2009292908A1/en
Application granted granted Critical
Publication of AU2009292908B2 publication Critical patent/AU2009292908B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009292908A 2008-09-22 2009-09-22 Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine Ceased AU2009292908B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9894508P 2008-09-22 2008-09-22
US61/098,945 2008-09-22
PCT/US2009/057750 WO2010033954A2 (en) 2008-09-22 2009-09-22 Galenical formulations of organic compounds

Publications (2)

Publication Number Publication Date
AU2009292908A1 AU2009292908A1 (en) 2010-03-25
AU2009292908B2 true AU2009292908B2 (en) 2012-07-26

Family

ID=42040192

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009292908A Ceased AU2009292908B2 (en) 2008-09-22 2009-09-22 Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine

Country Status (21)

Country Link
US (1) US8613949B2 (enExample)
EP (1) EP2328564A2 (enExample)
JP (2) JP2012503020A (enExample)
KR (1) KR20110060942A (enExample)
CN (1) CN102159195A (enExample)
AR (1) AR073384A1 (enExample)
AU (1) AU2009292908B2 (enExample)
BR (1) BRPI0919350A2 (enExample)
CA (1) CA2736257A1 (enExample)
CL (1) CL2011000594A1 (enExample)
CO (1) CO6351711A2 (enExample)
EC (1) ECSP11010999A (enExample)
IL (1) IL211571A0 (enExample)
JO (1) JO3239B1 (enExample)
MA (1) MA32719B1 (enExample)
MX (1) MX2011002988A (enExample)
MY (1) MY153610A (enExample)
PE (1) PE20110293A1 (enExample)
RU (2) RU2011115712A (enExample)
TW (1) TW201016217A (enExample)
WO (1) WO2010033954A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110268797A1 (en) * 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN103070863A (zh) * 2011-10-25 2013-05-01 河南省健康伟业生物医药研究股份有限公司 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061622A1 (en) * 2006-11-07 2008-05-29 Novartis Ag Crystalline forms of aliskiren hemifumarate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032954A1 (en) * 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Stabilized pharmaceutical formulations containing amlodipine maleate
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NZ536555A (en) 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
DE10223282B3 (de) 2002-05-24 2004-02-05 Orga Kartensysteme Gmbh Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst
FR2853904B1 (fr) 2003-04-15 2007-11-16 Air Liquide Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch
NZ586285A (en) * 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
EP1814527B2 (en) * 2004-11-05 2020-11-18 Boehringer Ingelheim International GmbH Bilayer tablet comprising telmisartan and amlodipine
US20060116435A1 (en) * 2004-12-01 2006-06-01 Housel Tyler L High strength polyurethane foam
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
PE20080991A1 (es) * 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061622A1 (en) * 2006-11-07 2008-05-29 Novartis Ag Crystalline forms of aliskiren hemifumarate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAIDYANATHAN et al. 'Int. J. Clin. Pract.' 2006, vol. 60 page 1343-1356 *

Also Published As

Publication number Publication date
WO2010033954A2 (en) 2010-03-25
ECSP11010999A (es) 2011-06-30
EP2328564A2 (en) 2011-06-08
IL211571A0 (en) 2011-05-31
WO2010033954A3 (en) 2010-10-21
BRPI0919350A2 (pt) 2015-12-29
RU2014140552A (ru) 2015-06-20
CL2011000594A1 (es) 2011-08-05
MX2011002988A (es) 2011-04-11
CN102159195A (zh) 2011-08-17
AU2009292908A1 (en) 2010-03-25
RU2011115712A (ru) 2012-10-27
JO3239B1 (ar) 2018-03-08
US20110165240A1 (en) 2011-07-07
US8613949B2 (en) 2013-12-24
MA32719B1 (fr) 2011-10-02
JP2012503020A (ja) 2012-02-02
JP2015091830A (ja) 2015-05-14
TW201016217A (en) 2010-05-01
CA2736257A1 (en) 2010-03-25
AR073384A1 (es) 2010-11-03
CO6351711A2 (es) 2011-12-20
KR20110060942A (ko) 2011-06-08
PE20110293A1 (es) 2011-05-17
MY153610A (en) 2015-02-27

Similar Documents

Publication Publication Date Title
AU2009202069B2 (en) Galenic formulations of organic compounds
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
AU2008309058B2 (en) Galenical formulations of Aliskiren and Valsartan
AU2009292908B2 (en) Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine
US20110177166A1 (en) Galenical Formulation Comprising Aliskiren and Process for its Preparation by Melt Extrusion Granulation
AU2008303504B2 (en) Galenical formulations of Aliskiren
US20120003308A1 (en) Pharmaceutical Composition Comprising Aliskiren
US20120009257A1 (en) Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired